Belgium· BE-AMP-SAM473635-00
Nevanac 3 mg/ml
A nepafenac product containing nepafenac, registered in Belgium by Novartis Europharm. The same ATC class is registered in 14 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Nepafenac is registered in 14 of 19 countries.
Countries holding a registration under ATC S01BC10 (nepafenac), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 8 of them publish a price we can compare per daily dose
Nepafenac · ATC S01BC10
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Nepafenac
- Manufacturer
- Novartis Europharm
- Country
- Belgium (BE)
- ATC code
- S01BC10
- ATC class
- Nepafenac
- Defined daily dose
- 0.15 mg, AT
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 3
- be_apb4363529
- be_apb4954848
- be_apb3028941
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
81 interactions on record for nepafenac.
Graded by severity as the source publishes them — 81 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Nepafenac · interactions on record
81 records
- 81 moderate
Most severe, free to view
- DicoumarolB01AA01moderate
- WarfarinB01AA03moderate
- HeparinB01AB01moderate
- Antithrombin IIIB01AB02moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Nepafenac in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaNEVANACNovartis Europharm Limited, Dublin
- NorwayNevanacNovartis Pharma GmbH
- United StatesILEVROHarrow Eye, LLC
- IcelandNevanacNovartis Europharm Limited*
- NetherlandsNevanac 3 mg/ml oogdruppels, suspensieNovartis Europharm Limited
- SwedenNEVANAC 3 mg/ml Ögondroppar, suspensionNovartis Europharm Limited
- PolandNevanacNovartis Europharm Limited
- FinlandNevanacNovartis Europharm Limited
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- Bulgaria · Апфекто
- Iceland · Nevanac
- Liechtenstein · Nevanac
- Norway · Nevanac
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/30d4c744-bbc8-44f0-995e-cd4c292c6b61 GET /v1/drugs/30d4c744-bbc8-44f0-995e-cd4c292c6b61?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Eye drops, suspension",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Nevanac 3 mg/ml",
"name_fr": "Nevanac 3 mg/ml",
"name_nl": "Nevanac 3 mg/ml",
"amp_code": "SAM473635-00",
"strengths": [
"3.0000",
"3.0000"
],
"pack_count": 4,
"substances": [
"Nepafenac"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Nepafenac",
"authorisation_numbers": [
"EU/1/07/433/002",
"EU/1/07/433/003"
]
}See everything about nepafenac.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.